Biocon Q4 profit drops 57%, but biosimilars business shines
Published on: May 8, 2026, 11:12 a.m. | Source: The Hindu Business Line
Biocon's Q4 profit drops 57% due to exceptional items, but biosimilars and generics segments show strong growth.
Want to grow your business digitally?
Let us help you get there—fast, smart, and effective.
Kunjesh Investment Banking – Trusted Since 2001
Financial Planning • Insurance • Investments • Retirement & Wealth Management. Personalized strategies, expert guidance, lasting success.
Get Started